TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9207639

Group type: EXPERIMENTAL
Intervention: Insulin-treated diabetic patients
Number of subjects: 41921

Group type: EXPERIMENTAL
Intervention: Non-insulin-treated diabetic patients
Number of subjects: 41921

Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 41921

Group type: EXPERIMENTAL
Intervention: Diabetic patients receiving accelerated t-PA
Number of subjects: 41921

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 41921

Group type: EXPERIMENTAL
Intervention: Diabetic patients undergoing coronary artery bypass graft surgery
Number of subjects: 41921

Group type: COMPARATOR
Intervention: Nondiabetic patients undergoing coronary artery bypass graft surgery
Number of subjects: 41921
Study: 8168798

Group type: EXPERIMENTAL
Intervention: Psychiatric treatment in jail
Number of subjects: 231

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 231
Study: 2889457

Group type: EXPERIMENTAL
Intervention: CGP 361 A (10 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propranolol (10 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diazepam (5 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 29297265

Group type: EXPERIMENTAL
Intervention: Binaural beats stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control stimulation
Number of subjects: 0
Study: 27106794

Group type: EXPERIMENTAL
Intervention: Beger procedure
Number of subjects: 65

Group type: COMPARATOR
Intervention: Berne modification
Number of subjects: 65
Study: 25957748

Group type: EXPERIMENTAL
Intervention: 10 mg dronabinol (Marinol®)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 20 mg dronabinol (Marinol®)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dronabinol (10 mg and 20 mg)
Number of subjects: 24
Study: 23999456

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 1615

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1615
Study: 21327759

Group type: EXPERIMENTAL
Intervention: Nicotine administration in abstinent smokers
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Alcohol administration in abstinent smokers
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo administration in abstinent smokers
Number of subjects: 109
Study: 19290702

Group type: EXPERIMENTAL
Intervention: Face-to-face intervention
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Computerized intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 84
Study: 17728959

Group type: EXPERIMENTAL
Intervention: Full-field digital mammography (FFDM)
Number of subjects: 2734

Group type: EXPERIMENTAL
Intervention: Computed radiography mammography (CRM)
Number of subjects: 2734

Group type: COMPARATOR
Intervention: Screen-film mammography (SFM)
Number of subjects: 2734
Study: 15176654

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg formulation 1
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg formulation 2
Number of subjects: 23

Group type: COMPARATOR
Intervention: Pravastatin 20 mg formulation 1 and 2
Number of subjects: 23
Study: 11205494

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for Helicobacter pylori infection and daily dietary supplementation with antioxidant micronutrients
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: Baseline KRAS mutations
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: KRAS mutation in 72-month biopsies
Number of subjects: 863
Study: 9466971

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg daily)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 8955577

Group type: EXPERIMENTAL
Intervention: Histamine release (HR) with commercial extract
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Specific IgE analyses (three commercially available tests)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Freshly prepared codfish extracts with HR
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Phadebas RAST, CAP, and in-house RAST
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Magic Lite (ML)
Number of subjects: 38
Study: 2082886

Group type: EXPERIMENTAL
Intervention: Cord drainage of placental blood
Number of subjects: 1908

Group type: COMPARATOR
Intervention: Control group (cord clamped)
Number of subjects: 1908
Study: 395826

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 663

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 663
Study: 31352473

Group type: EXPERIMENTAL
Intervention: Standard treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive nodal observation
Number of subjects: 0
Study: 27943008

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 469
Study: 25786517

Group type: EXPERIMENTAL
Intervention: Mitral isthmus (MI) ablation from the left inferior PV to the posterior mitral annulus (group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mitral isthmus (MI) ablation from the left inferior PV to the anterolateral mitral annulus (group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Incomplete MI block
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Length of the MI
Number of subjects: 40
Study: 25336068

Group type: EXPERIMENTAL
Intervention: Hatha yoga intervention (12-week, twice-weekly)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 200
Study: 24168465

Group type: EXPERIMENTAL
Intervention: Nurse-based case management (n=161) including home visits and telephone calls for one year.
Number of subjects: 340

Group type: COMPARATOR
Intervention: Usual care (n=168).
Number of subjects: 340
Study: 21167355

Group type: COMPARATOR
Intervention: No ICD
Number of subjects: 6378
Study: 18307484

Group type: EXPERIMENTAL
Intervention: Spontaneous pushing technique (open glottis pushing while breathing out)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Valsalva-type pushing technique (closed glottis pushing while holding their breath)
Number of subjects: 100
Study: 16542201

Group type: EXPERIMENTAL
Intervention: Tezosentan (2.5, 5.0, 12.5 and 25 mg h(‐1))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tezosentan
Number of subjects: 24
Study: 12703845

Group type: EXPERIMENTAL
Intervention: First series of tests (five 10 min sub‐maximal cycle exercise bouts, VO2peak test, 115% VO2peak test)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Second series of tests (15 min incremental cycle ergometer test followed by a 2 min variable resistance test)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Modified protocol (second series)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Modified 2 min maximal test
Number of subjects: 10
Study: 11121631

Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (no amifostine)
Number of subjects: 35
Study: 9489813

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment for RA
Number of subjects: 26
Study: 7836695

Group type: COMPARATOR
Intervention: D-propoxyphene (0.7 mg/kg body weight)
Number of subjects: 29
Study: 3402341

Group type: EXPERIMENTAL
Intervention: Cavafix catheter
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Early catheter removal
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Routine weekly catheter replacement
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Nursing and supervision by trained personnel
Number of subjects: 3000
Study: 29659956

Group type: EXPERIMENTAL
Intervention: Grape juice polyphenols (GJPs) 300 mg/d for 1 month
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 40
Study: 28626018

Group type: EXPERIMENTAL
Intervention: Hippocampal oscillations under conflict
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Theta oscillations
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Gamma power modulation
Number of subjects: 23
Study: 26053138

Group type: EXPERIMENTAL
Intervention: 300 mg of galactose/day followed by 500 mg for 2 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (13 patients)
Number of subjects: 26
Study: 23641006

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) ON
Number of subjects: 419
Study: 21139035

Group type: EXPERIMENTAL
Intervention: Conventional acupuncture
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 36
Study: 19051551

Group type: EXPERIMENTAL
Intervention: Rembrandt Plus‐‐peroxide whitening rinse
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Listerine‐‐alcohol containing
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral B‐‐alcohol free
Number of subjects: 30

Group type: COMPARATOR
Intervention: 10% carbamide peroxide bleaching agent (Vivastyle)
Number of subjects: 30
Study: 16815189

Group type: EXPERIMENTAL
Intervention: Inhaled morphine (65 mug kg(‐1) morphine sulphate, 3 mL via oral nebulizer)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (physiological saline, 3 mL via oral nebulizer)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Inhaled morphine
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.9% sodium chloride
Number of subjects: 80
Study: 15124547

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (20-25 Gy) in stage I seminoma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surveillance instead of postoperative radiotherapy in stage I seminoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy limited to the paraortic area in stage IIa seminoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy in stage IIb and higher seminoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Association of carboplatin and radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel radiotherapeutic approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cryptorchid seminoma and HCG-producing seminoma
Number of subjects: 0
Study: 10882586

Group type: EXPERIMENTAL
Intervention: Protease inhibitor-containing regimen
Number of subjects: 147

Group type: COMPARATOR
Intervention: Dual nucleoside analogue regimen
Number of subjects: 147
Study: 8672377

Group type: EXPERIMENTAL
Intervention: Subanaesthetic isoflurane 0.16 vol%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Subanaesthetic isoflurane 0.24 vol%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Subanaesthetic isoflurane 0.08 vol%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All concentrations of isoflurane (0.08, 0.16, 0.24 vol%)
Number of subjects: 10
Study: 7565327

Group type: EXPERIMENTAL
Intervention: Ciprofloxacine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symptomatic therapies, ampicillin, co‐trimoxazole
Number of subjects: 0
Study: 3344730

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 64
Study: 31056570

Group type: EXPERIMENTAL
Intervention: Intralesional Triamcinolone Acetonide (TA)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Incision and Curettage (I&C)
Number of subjects: 118
Study: 28596103

Group type: EXPERIMENTAL
Intervention: Training intervention for GPs (9 hours of interactive training on youth-friendly care, psychosocial health risk screening, and motivational interviewing)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Training intervention for GPs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no training intervention)
Number of subjects: 40
Study: 26222093

Group type: EXPERIMENTAL
Intervention: M Technique (structured touch)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 225

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 225
Study: 23724526

Group type: EXPERIMENTAL
Intervention: Ondansetron (OND)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Metoclopramide (MET)
Number of subjects: 83
Study: 20492840

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg/d)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 115
Study: 19016988

Group type: EXPERIMENTAL
Intervention: Hemodynamic Assessment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Manual Assessment
Number of subjects: 200
Study: 17012455

Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate 20 mg, administered three times per day for 1 week, then 20 mg per day for the next 3 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Monophasic combination oral contraceptive (OC) containing 1 mg norethindrone and 35 mcg of ethinyl estradiol, administered three times per day for 1 week, then one tablet per day for the next 3 weeks
Number of subjects: 40
Study: 15040791

Group type: COMPARATOR
Intervention: Patient information booklet about menorrhagia and treatment options, mailed before the first visit to the outpatient clinic.
Number of subjects: 363
Study: 10740328

Group type: EXPERIMENTAL
Intervention: Oral trimegestone (0.05, 0.1, 0.25 and 0.5 mg per day)
Number of subjects: 176
Study: 9415221

Group type: EXPERIMENTAL
Intervention: Amorphous injectable form of aztreonam (BIOKTAM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: AZACTAM
Number of subjects: 0
Study: 1280464

Group type: EXPERIMENTAL
Intervention: Additional radiotherapy after chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional radiotherapy for nodular sclerosis histology subgroup
Number of subjects: 0

Group type: COMPARATOR
Intervention: No further treatment or additional chemotherapy
Number of subjects: 0
Study: 6424827

Group type: EXPERIMENTAL
Intervention: Early (aggressive) surgical management
Number of subjects: 142

Group type: COMPARATOR
Intervention: Delayed (conservative) policy
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Early surgical management for gastric ulcer
Number of subjects: 142

Group type: COMPARATOR
Intervention: Delayed surgical management for gastric ulcer
Number of subjects: 142
Study: 30865315

Group type: EXPERIMENTAL
Intervention: 75-mg single-dose solriamfetol in normal renal function
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 75-mg single-dose solriamfetol in mild renal impairment
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 75-mg single-dose solriamfetol in moderate renal impairment
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 75-mg single-dose solriamfetol in severe renal impairment
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 75-mg single-dose solriamfetol in ESRD without hemodialysis
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 75-mg single-dose solriamfetol in ESRD with hemodialysis
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 75-mg single-dose solriamfetol in ESRD with and without hemodialysis
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 75-mg single-dose solriamfetol during hemodialysis
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Adverse events related to solriamfetol
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Study drug-related adverse events
Number of subjects: 37
Study: 30583748

Group type: EXPERIMENTAL
Intervention: Circulating bio‐ADM levels upon admission > 70 pg/ml
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Persistently elevated bio‐ADM at day 2
Number of subjects: 583
Study: 26992115

Group type: EXPERIMENTAL
Intervention: Bioabsorbable steroid-eluting sinus implant (mometasone furoate)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 100
Study: 25262257

Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy (DAPT)
Number of subjects: 3691

Group type: COMPARATOR
Intervention: Single-antiplatelet therapy (SAPT)
Number of subjects: 3691

Group type: EXPERIMENTAL
Intervention: DAPT
Number of subjects: 3691

Group type: COMPARATOR
Intervention: SAPT
Number of subjects: 3691
Study: 22301127

Group type: EXPERIMENTAL
Intervention: Automated Diabetes Management System (ADMS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional care without technology (Control)
Number of subjects: 48
Study: 19626571

Group type: EXPERIMENTAL
Intervention: Early repair of episiotomy before expulsion of placenta (Group 1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Repair of episiotomy after spontaneous placental expulsion (Group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 17436202

Group type: EXPERIMENTAL
Intervention: Echinacea supplement for 4 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 32
Study: 16214443

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment for 6 months
Number of subjects: 75
Study: 12001761

Group type: EXPERIMENTAL
Intervention: Valproate or carbamazepine in monotherapy or combination of phenobarbital and phenytoin and the combination of phenobarbital, phenytoin and primidone in polytherapy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Group E (women with epilepsy)
Number of subjects: 53
Study: 10544903

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UH) given as an intravenous bolus of 80 U/kg followed by a constant infusion of 18 U/kg/h
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nadroparin 185 AXa IU/kg once daily subcutaneously
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Secondary endpoints
Number of subjects: 20
Study: 7792126

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil (8 mg/kg/day twice daily)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate (amoxicillin 40 mg/kg/day 3 times a day)
Number of subjects: 348
Study: 1977256

Group type: EXPERIMENTAL
Intervention: EMLA cream applied for 30, 60, 90, and 120 min on various body locations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EMLA cream on the back.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EMLA cream in the cubital fossa and on the hand.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of cutaneous blood flow.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidermal and dermal thickness measurements.
Number of subjects: 0
Study: 6778189

Group type: EXPERIMENTAL
Intervention: tocainide
Number of subjects: 146

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 146
Study: 31505520

Group type: EXPERIMENTAL
Intervention: Anxiety NOS diagnosis based on electronic medical record
Number of subjects: 61

Group type: COMPARATOR
Intervention: Structured diagnostic interview
Number of subjects: 61
Study: 27964962

Group type: EXPERIMENTAL
Intervention: PUSH (multi-component physiotherapy intervention based on aerobic conditioning, specificity of training, and muscle overload)
Number of subjects: 210

Group type: COMPARATOR
Intervention: PULSE (non-specific multi-component control physiotherapy intervention including transcutaneous electrical nerve stimulation, flexibility activities, and active range of motion exercises)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: PUSH
Number of subjects: 210

Group type: COMPARATOR
Intervention: PULSE
Number of subjects: 210
Study: 25533243

Group type: EXPERIMENTAL
Intervention: 5Hz‐rTMS (treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham (placebo) stimulation
Number of subjects: 0
Study: 23647888

Group type: EXPERIMENTAL
Intervention: High-saturated fatty acid (HSFA) diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-monounsaturated fatty acid (HMUFA) diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate diet supplemented with n-3 polyunsaturated fatty acids (LFHCC n3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate diet (LFHCC)
Number of subjects: 0
Study: 20144522

Group type: EXPERIMENTAL
Intervention: Parent-physician communication skills training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 28
Study: 19494551

Group type: EXPERIMENTAL
Intervention: Combination of tests for orientation, memory, attention, executive function, and abstraction and judgment
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Combination of tests for memory, attention, executive function, and abstraction and judgment (excluding orientation)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Mini Mental State Examination
Number of subjects: 625
Study: 16423089

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg q.d., esomeprazole 20 mg b.i.d., and amoxicillin 1 g b.i.d.
Number of subjects: 85

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d.
Number of subjects: 85
Study: 15598479

Group type: COMPARATOR
Intervention: Gefitinib 250 mg tablet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gefitinib dispersion preparation via drink
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gefitinib dispersion preparation via nasogastric tube
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) related to gefitinib
Number of subjects: 18
Study: 11306524

Group type: EXPERIMENTAL
Intervention: CEE+MP (micronized progesterone 200 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CEE+MPA (medroxyprogesterone acetate 10 mg)
Number of subjects: 20
Study: 9403262

Group type: EXPERIMENTAL
Intervention: Betadine cold sore paint
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Stoxil topical ointment
Number of subjects: 72

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 72
Study: 8427753

Group type: EXPERIMENTAL
Intervention: Iodixanol 320 mg I/ml
Number of subjects: 72

Group type: COMPARATOR
Intervention: Iohexol 350 mg I/ml
Number of subjects: 72
Study: 3298649

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29032139

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg twice daily (50 mg once daily if treated with a sulfonylurea)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 254
Study: 27772790

Group type: EXPERIMENTAL
Intervention: Cold air chamber at -60°C (n=12)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Local cryotherapy at -17°C (n=11)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cold air chamber at -10°C (n=12)
Number of subjects: 35